Ajanta Pharma today reported 11.60 per cent rise in consolidated net profit at Rs 105.79 crore for the June quarter on account of robust sales in branded generic business.
The company had posted a net profit of Rs 94.79 crore in the year-ago period, Ajanta Pharma said in a BSE filing.
Consolidated income from operations stood at Rs 510.99 crore for the reported quarter. It was Rs 473.12 crore for the same period a year ago.
"We are pleased with our June quarter performance which is in line with our expectations. Branded generic business in India and Export markets posted healthy growths," MD Yogesh Agrawal said.
Despite challenging pricing environment in the US, the company has posted healthy growth for the quarter, he added.
"Going forward, branded generic business in India and Emerging Markets, and generic business in the US will be key focus markets for us," Agrawal said.
Shares of Ajanta Pharma were today trading at Rs 1,140.35 per scrip on BSE, up 1.01 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
